n America and Europe, the current recommended dose of recombinant tissue-type plasminogen activator (r-tPA) for acute ischemic stroke is 0.9 mg/kg, but a similar study with this dosage has never been replicated in a controlled trial in East Asia. A lower dose (0.6 mg/kg) of r-tPA was used in Japan and was proved to have similar outcomes compared with a dose of 0.9 mg/kg in Western countries.
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Because the ranges of the lower dose observed in the study were wide (from 0.55 to 0.84 mg/kg) and the population of 241 was relatively small, we conducted the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke Study II (TTT-AIS II) to determine the optimal dose of r-tPA for acute ischemic stroke in Chinese or East Asian patients by prospective patient registration and dose/safety/efficacy analysis.
Methods
Study Design and Participants
The TTT-AIS II was the continuation of the TTT-AIS study, which was a prospective multicenter observational study performed in most hospitals using r-tPA treatment for acute ischemic stroke in Taiwan. It was similar to the SITS-MOST study, which was an Internet-based, academic, interactive thrombolysis therapy registration. 4 The detailed study design has been published elsewhere. 5 The r-tPA indications and exclusion criteria were similar to the SITS-MOST study, including an upper age limit of 80 years. Because several studies implied that it is more appropriate to use a lower dose of anticoagulants or r-tPA in Chinese patients than in white patients, some neurologists in Taiwan inferred that the dose of r-tPA for acute ischemic stroke should also be reduced for safety concerns. 6, 7 Some doctors applied r-tPA to patients aged >80 years, which was officially considered off-label use of r-tPA in Taiwan. In this study, we asked investigators to enter the total dose of r-tPA administered in the emergency room and then enter the exact body weight when the patients were later weighed during their hospitalization. The exact unit dose was calculated as the total dose divided by the exact body weight. Kaohsiung Medical University Hospital's institutional review board approved the study proposal, and we obtained written informed consent from all patients. The registration started in December 2004 and ended in November 2011.
Outcome Measures
The safety outcome of the TTT-AIS II study was the occurrence of SICH and death within 3 months. We defined SICH as the National Institute of Neurological Disorders (NINDS) study did: ICH with the deterioration of any neurological symptoms (National Institutes of Health Stroke Scale score ≥1) or death. 8 The radiological definition of hemorrhagic events followed the European Cooperative Acute Stroke Study (ECASS) classification. 9 In the safety analysis, patients aged >80 years were excluded from the analysis because they were not considered eligible for r-tPA treatment in Taiwan. The efficacy outcome was functional outcomes, including the modified Rankin Scale (mRS) and the Barthel index, at 3 months after treatment. An mRS score of 0 to 1 was considered a good functional outcome; an mRS score of 0 to 2 was considered functional independence. Only 840 patients, aged ≤80 years and with a prestroke disabled state mRS score of 0 to 1, were included in the efficacy analysis, because patients with a prestroke disabled state mRS score >1 have no chance of getting good clinical outcomes with mRS 0 to 1. For comparison with other studies reported in the literature, data from the total 1004 patients were included, and we also added the outcome of the incidence rate of SICH as defined in the SITS-MOST and ECASS studies.
Statistical Analysis
Data were analyzed using SAS 9.2 software. The means±SD (for continuous variables) or percentages (for discrete variables) were calculated for all baseline data. Groups were compared using the Student t test for continuous variables and the χ 2 test for discrete variables. Mantel-Haenszel extension χ 2 tests were conducted for trend analyses of dose responses to SICH. Odds ratios were calculated for all discrete variables to identify risk factors in univariate and multivariate analyses for SICH and good functional outcome. Multiple logistic regression with backward elimination was conducted to evaluate the risk factors associated with SICH and good functional outcome. All statistically significant levels were defined as P<0.05.
Results
From December 2004 to November 2011, eligible patients with acute ischemic stroke who received thrombolytic therapy at 23 hospitals in Taiwan were registered. Five patients' data were excluded because r-tPA administration was stopped prematurely during infusion because of a rapid deterioration of the patients' vital signs; these patients initially fulfilled the indications for r-tPA treatment. Thus, the data from 1004 patients were included for safety, efficacy, and dose-response analyses. Of these, 976 (97.2%) completed the 1-month follow-up and 960 (95.6%) completed the 3-month mRS; all patients completed the baseline image reports and the followup image reports.
We classified an average dose of 0.9 mg/kg (0.86-0.95; 422 patients; mean, 0.91±0.05 mg/kg; median, 0.9 mg/kg; range, 0.86-1.26 mg/kg) as the dose of 0.9 mg/kg group. Doses ≤0.85 mg/kg were categorized as the low-dose group, which was further divided into 3 subgroups: 0.8 mg/kg (202 patients; mean, 0.81±0.03 mg/kg; median, 0.81 mg/kg; range, 0.76-0.85 mg/kg), 0.7 mg/kg (199 patients; mean, 0.71±0.02 mg/kg; median, 0.71 mg/kg; range, 0.68-0.75 mg/kg), and 0.6 mg/kg (181 patients; mean, 0.62±0.04 mg/kg; median, 0.61 mg/kg; range, 0.55-0.65 mg/kg). In total, 42.0% of the patients were treated with the dose of 0.9 mg/kg, and 58.0% were treated with a lower dose (20.1% with 0.8 mg/kg, 19.8% with 0.7 mg/kg, and 18.0% with 0.6 mg/kg). The distributions of the r-tPA dose used in medical centers and community hospitals were similar. Table 1 shows the baseline data and demographics of the patients with various doses. As a result of the observational nature of study design, baseline characteristics were not completely comparable among different treatment arms. Patients given the lower dose were more likely to be older, have atrial fibrillation, have a longer time to treatment, and also have less hyperlipidemia and less current smoking.
The safety and efficacy results compared with other studies are summarized in Table I in the online-only Data Supplement. Overall, the occurrence of SICH per the NINDS definition and death after r-tPA were comparable with the results of the SITS-MOST, NINDS, Japan Alteplase Clinical Trial (J-ACT), Japan Post-Marketing Alteplase Registration Study (J-MARS), and SITS-NEW studies, but the percentage of good functional outcomes at 3 months (30.6%) was less than that in those studies and in our previous report (39.3%). 5 The univariate analyses of safety showed that using a dose of r-tPA of 0.9 mg/kg, age, hypertension, coronary heart disease, clopidogrel/ticlopidine use, and aspirin use influenced the occurrence of SICH per the NINDS definition. In contrast, current smoking was negatively associated with the occurrence of SICH. After adjusting for potential confounders, multiple regression analysis showed that using a dose of 0.9 mg/kg of r-tPA, hypertension, and coronary heart disease were the independent predictors of SICH occurrence after r-tPA treatment; in addition, current smoking was a protective factor for SICH occurrence ( Table 2 ).
The efficacy of r-tPA treatment was expressed as the percentage of patients who had a good functional outcome (mRS score 0-1) at 3 months. Univariate analyses showed that dose ≤0.65 mg/kg, baseline National Institutes of Health Stroke Scale score, age, and absence of diabetes mellitus were the predictors of good clinical outcomes. Multivariate analyses after adjusting for the covariates showed that r-tPA dose ≤0.65 mg/kg, age, National Institutes of Health Stroke Scale score, and absence of diabetes mellitus were independently related to an mRS score of 0 to 1 at 3 months (Table 3) . The safety and efficacy outcomes of the 4 groups with different r-tPA doses are shown in Table II in the online-only Data Supplement. Overall, there were no differences in safety or efficacy outcomes among the 4 dose groups. However, after accounting for age and dose interaction, there were differences in both the safety and efficacy outcomes in patients aged >70 years (71-80 years) among the 4 dose groups. The effects of interactions between age and r-tPA dose on the occurrence of SICH are illustrated in Figure 1 . The occurrence of SICH increased after r-tPA treatment as age increased (P=0.002; Figure 1A ), but SICH increased with increasing doses of r-tPA only in patients aged >70 years (71-80 years; P=0.0130; Figure 1B ). This trend was not observed in younger patients.
In patients aged >70 years, as the dose of r-tPA increased, the frequency of a better functional outcome at 3 months decreased (P=0.0179 for mRS 0-1 and P=0.0180 for mRS 0-2; Figure 2A and 2B) and the mortality rates increased (P=0.0971; Figure 2C ). We also found that using a lower r-tPA dose of 0.6 mg/kg compared with a dose of 0.9 mg/kg was associated with higher rates of good functional outcomes (mRS 0-1; 41.3% versus 22.9%; absolute difference, 18.4%; relative increase in good functional outcome, 80.4%), independent functional outcomes (mRS 0-2; 54.0% versus 33.6%; absolute difference, 20.4%; relative increase in independent functional outcome, 60.7%), and a lower mortality rate at 3 months (4.6% versus 12.4%; absolute difference, 7.8%; relative mortality reduction, 72.8%; Table III in the online-only Data Supplement).
Discussion
This study did not support the dose of 0.9 mg/kg of r-tPA for all Chinese patients, especially for patients aged >70 years. In our study population, a dose of 0.9 mg/kg of r-tPA was related to more SICH, and a dose of ≤0.65 mg/kg was associated with a good functional outcome in a multivariate logistic regression analysis. In patients aged >70 years, an r-tPA dose of 0.6 mg/kg has better safety (lower SICH and mortality rates) and functional outcomes at 3 months compared with higher doses. Our study suggests an optimal dose of 0.6 mg/kg of r-tPA, which has better safety and efficacy in aged Chinese patients with acute ischemic stroke. In this study, 120 patients who received thrombolytic therapy were >80 years of age, which accounted for ≈12% of all the patients given thrombolytic therapy, although they are not officially considered eligible for r-tPA therapy in Taiwan. The analysis of the data in patients aged >80 years revealed no significant differences among groups of different r-tPA doses. It was mainly because of poor clinical outcomes, in general, across the groups of different r-tPA doses and small number of patients in each dose group. Owing to inconclusive results and failure to provide useful information after the analysis of data among the patients aged >80 years, we did not present the results of those patients. However, the study of the safety and efficacy of the patients aged >80 years is underway in Taiwan, initiated by Taiwan Stroke Society, and hopefully, we can provide more information in the near future. The impact of different r-tPA doses on patient outcomes is rarely discussed in international neurological societies, with the exception of a few small studies in certain Asian countries. 10 , 11 The present study is the first that registered enough East Asian patients receiving various doses of r-tPA to analyze the relationship between the dose and the safety/efficacy in acute ischemic stroke. Our study echoes the findings of previous studies that higher doses of thrombolytic agents increase the risk of hemorrhage and reveals higher rates of SICH per the NINDS definition (12.4%) in elderly patients (71-80 years) receiving 0.9 mg/kg of r-tPA (Table III in the onlineonly Data Supplement) . [12] [13] [14] In the SITS-NEW study in Asian countries, which used 0.9 mg/kg of r-tPA for acute ischemic stroke, the rate of SICH per the NINDS definition (8.7%) was higher than those r-tPA studies previously reported (Table I in the online-only Data Supplement), despite the fact that the patient population was younger in the SITS-NEW study than in the TTT-AIS II study (median age, 64 versus 68 years).
In this study, the risk factors for SICH were similar to those reported elsewhere. 15 Interestingly, the findings in this study echo the so-called smoking-thrombolysis paradox, that is, significantly less ICH occurs in smokers after thrombolytic therapy. 16 Patients with current or recent smoking were also reported to paradoxically have higher rates of recanalization and better outcomes than nonsmokers after thrombolytic therapy. 17 However, our present study did not find an association between smoking and functional outcome.
For comparison with other studies reported in the literature, data from the total 1004 patients were included. Although our present study had comparable rates of SICH and mortality, the rate of good functional outcome (30.6%) was lower than our previous TTT-AIS study (39.3%) and the SITS-NEW ) . B, After considering the age and dose interaction, a significant trend for SICH with dose was also found in patients aged 71 to 80 years (right bar chart). SICH rates were lower in younger patients with various doses and in those aged 71 to 80 years using the lowest dose. Figure 2 . Distribution of modified Rankin Scale (mRS) scores (0-1, 0-2) at 3 months and death within 3 months in patients aged ≤70 and 71 to 80 years treated with different doses. Better outcomes were observed in the younger patients with various doses and in those aged 71 to 80 years who received the lowest dose. A, A significant trend for good functional outcome (mRS 0-1) with dose was observed in patients aged 71 to 80 years (right bar chart), and no difference in the younger patients with various doses was observed (left bar chart). B, A significant trend for mRS 0 to 2 with dose was also observed in patients aged 71 to 80 years (right bar chart), and no difference for mRS 0 to 2 in the younger patients was observed (left bar chart). C, A trend toward less mortality using the lowest dose compared with a dose of 0.9 mg/kg in patients aged 71 to 80 years was observed (right bar chart).
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August 2014 study (Table I in the online-only Data Supplement). This can be partially explained by the fact that the current study population had a higher mean age, a higher baseline National Institutes of Health Stroke Scale score, a longer mean time from stroke onset to treatment, and higher frequencies of hypertension, diabetes mellitus, atrial fibrillation, and aspirin and clopidogrel use. In addition, patients with recurrent stroke (12%) and a prestroke mRS score ≥2 were still included for thrombolytic therapy in the present study. All the above-mentioned factors may be legitimate reasons for the lower rate of good functional outcomes observed in the present study. It has been reported that the incidence of ICH was 2-fold higher in Asians compared with whites, and the prevalence of microbleeds and the susceptibility to spontaneous ICH were also higher in Asians compared with non-Asians. 18, 19 There is evidence that supports that maintaining a lower international normalized ratio level of warfarin for the secondary prevention of stroke in patients with nonvalvular atrial fibrillation is better for Chinese and Japanese patients compared with white patients. 20, 21 A recent study revealed that bleeding complication rates on warfarin were higher in Asians compared with non-Asians. 22 Thus, we speculate that racial/genetic difference is one of the determinant factors for drug dose, not only for anticoagulants (warfarin) but also probably for thrombolytic agents (r-tPA).
Many neurologist in Asian countries may use lower dose or variable dose of r-tPA regimens for acute ischemic stroke because of the fact that (1) Asians are more prone to bleeding, (2) the r-tPA dose of 0.9 mg/kg has never been replicated with controlled trial in East Asians, (3) the 0.6 mg/kg dose of r-tPA for stroke was approved and used in Japan, and (4) the cost of r-tPA. So, our present study, in addition to the previous TTT-AIS study, suggests a need for a randomized clinical trial to study the r-tPA dose in East Asian population, especially in the elderly patients. To date, there is no single randomized controlled trial published that has compared the safety/efficacy of r-tPA between the current 0.9 mg/kg dose and other lower doses. Of note, our results support the current ongoing study, the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED), with the dose of 0.6 versus 0.9 mg/kg. 23 We think that observational studies and randomized trials can complement each other; otherwise people will still argue why other lower dose such as 0.7 mg/kg or 0.8 mg/kg compared with 0.9 mg/kg is not used.
Our study design has limitations. Although the registration was prospective, the r-tPA dose selection was not randomized, and physicians might have selected the dose according to patients' clinical conditions, such as patient's imaging findings and medical comorbidity, which might influence the results of dose/safety/efficacy analysis. It is notable that patients who had unfavorable factors for stroke outcome, such as older age, atrial fibrillation, and longer time to r-tPA treatment, were more likely to receive a lower r-tPA dose (Table 1) 24,25 and, thus, would underestimate the benefits of the lower doses. However, we included all the clinical characteristics of the patients in the study and adjusted them for further dose outcome analyses.
In conclusion, the present study is the first to show the outcomes of thrombolytic therapy with various doses of r-tPA, and the dose of 0.6 mg/kg correlated to a better outcome for aged Chinese patients. Given the nature of the present study, randomized controlled trials are warranted to confirm the current findings. Supplemental Table I . 
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